Gilead Sciences ended the fourth quarter with results that exceeded Wall Street revenue expectations, yet the market responded negatively as investors focused on guidance and margin pressures. Management cited strong growth in its HIV business, including a 53% increase in the HIV prevention portfolio and rapid uptake of the new YES2GO injectable, as key drivers. CEO Daniel O’Day noted, “YES2GO is a transformative medicine that we expect to drive durable, steady, and long-term growth in our HIV prevention business.” However, continued headwinds in cell therapy and a notable drop in operating margin from last year contributed to investor concerns.

Is now the time to buy GILD? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Gilead Sciences’s Q4 Earnings Call

• Chris Schott (JPMorgan): asked for details on YES2GO’s $800 million guidance and patient refill rates. Chief Commercial and Corporate Affairs Officer Johanna Mercier explained strong early indicators but noted persistency data is still developing, with ongoing efforts to improve refill adherence.
• Louise Chen (Scotiabank): questioned expected market share for Anidocel in fourth-line multiple myeloma. Cindy Perettie, Executive Vice President of Kite, projected modest initial contribution in 2026 but outlined plans to become market leader over time due to efficacy and manufacturing advantages.
• Tazeen Ahmad (Bank of America): inquired about YES2GO’s impact on Descovy and net price trends. Mercier stated both products should grow through 2026, with YES2GO’s differentiated profile supporting price resilience.
• Geoffrey Meacham (Citibank): asked about the need for larger-scale business development or diversification. CEO Daniel O’Day said Gilead is disciplined and proactive, focusing on both early-stage deals and select late-stage acquisitions without urgency for major transactions.
• Tyler Van Buren (TD Cowen): sought insight on Trodelvy’s use ahead of formal frontline approval. Mercier confirmed increasing off-label adoption due to positive data and guideline inclusion, with frontline opportunity expected to double the addressable patient pool.

Catalysts in Upcoming Quarters

In coming quarters, the StockStory team will be watching (1) the pace of YES2GO adoption and refill persistence, (2) regulatory and commercial progress for Trodelvy and Anidocel launches, and (3) the impact of policy-driven pricing headwinds on HIV and liver franchises. Execution across these milestones will determine if Gilead can maintain growth despite external pressures.

Gilead Sciences currently trades at $155.38, up from $147.23 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.